AstraZeneca Sees Emerging Market Opportunity for Forest Anti-Infective

In years gone by, practically no Big Pharma would have signed a licensing deal that did not include U.S. rights. These days, however, the rise of China, India and other emerging markets is providing more geographic carve-out opportunities for deal-makers